<allTrials totalCount="41" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-08-08T00:00:00.000Z">67123277</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circadian intraocular pressure, blood pressure and diastolic ocular perfusion pressure with timolol-dorzolamide fixed combination compared with latanoprost in newly-diagnosed glaucoma patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the short-term effect of Timolol-Dorzolamide Fixed Combination (TDFC), and latanoprost 0.005% on the 24-hour Intraocular Pressure (IOP), ambulatory Blood Pressure (BP), and Diastolic Ocular Perfusion Pressure (DOPP), in newly-diagnosed Primary Open-Angle Glaucoma (POAG) patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at baseline, and at the end of each treatment period: 
1. 24-hour IOP
2. Ambulatory BP
3. Calculated DOPP</primaryOutcome>
      <secondaryOutcome>Adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of Clinica Oculistica Universit√† degli studi Brescia (ref: 02/2005/03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67123277</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, observer-masked, two-treatment, two-period cross-over study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8e3b6778-ef98-4ef0-ba21-ac7cd7366c21">
	  <name>Centro per lo studio del glaucoma</name>
	  <address/>
	  <city>Brescia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>25123</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>We enrolled in the present study consecutive newly diagnosed and previously untreated POAG patients who demonstrated typical optic disc excavation and visual field abnormalities. We included POAG patients older than 45 years with no previous history of ocular surgery or laser. Additional inclusion criteria were: 
1. Open-angle by gonioscopy (Grade III-IV according to Shaffer&#146;s grading system)
2. Untreated diurnal IOP between 23 and 32 mm Hg (mean of the two highest values recorded in a daytime IOP curve with measurements every 2 hours between 08:00 and 18:00 by a calibrated Goldmann applanation tonometry)
3. Visual acuity 20/40 or better
4. Mean defect &gt;6 dB using the Humphrey 24-2 program (Humphrey Visual Field Analyzer model 745 perimeter, Humphrey Instruments, Inc., USA)
5. No history of allergy to the ingredients of any of the study drugs
6. No history of cardiovascular disease (e.g. arterial hypertension, heart disease, arrhythmia)
7. No concomitant systemic treatment (e.g. beta-blockers, angiotensin-converting enzyme inhibitors) that could modify IOP, or blood pressure. 
8. Females were enrolled in the study only if they were postmenopausal or were using contraceptives</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>27</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>27</totalTarget>
      <exclusion>See inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary open-angle glaucoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Primary open-angle glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following the monitoring of the baseline or washout IOP and BP all study patients were randomly assigned to receive either one drop of TDFC twice daily (08:00 and 20:00) or one drop of latanoprost once in the evening (20:00). 

Twenty-four hour IOP and ambulatory BP were measured at the beginning after the interim washout and at the end of each treatment period, thus obtaining 4 circadian curves. At the time of 24-hour IOP and BP assessments patients were hospitalized, and the drugs were administered by the dosing coordinator of the study according to the protocol. 

The IOP was measured every two hours. A calibrated Goldmann applanation tonometer (Haag-Streit, Switzerland) was employed to measure sitting IOP at the slit lamp between 08:00 and 22:00, while supine IOP was measured between 24:00 and 06:00, with the patient in bed, by means of a calibrated handheld electronic tonometer (TonoPen XL; Bio-Rad, USA). At each timepoint, the mean of 3 consecutive readings was calculated. 

Ambulatory blood pressure monitoring was recorded by means of an automated portable BP device, TM-2430 (A&amp;D Co, Saitama, Japan). Ambulatory BP monitoring units indirectly measure BP through oscillometric measurement of the vibratory signals associated with blood flow in the brachial artery. The BP device satisfies the recommendation by the British Hypertension Society and Association for Advancement of Medical Instrumentation on accuracy levels for both systolic and diastolic blood pressures. A cuff of appropriate size was placed in the subject&#146;s non-dominant arm and BP measurements were taken automatically every 15 minutes between 08:00 to 22:00, and every 30 minutes from 22:00 to 08:00. If a certain reading was not performed properly the 
device was programmed to repeat it. The recorded BP values throughout the 24-hour period were later recovered from the recording chip and stored in a personal computer. 

During the study BP and IOP readings were monitored in the hospital on two separate days, so as to not influence BP readings by the process of IOP measurements, or by waking the patient during the night for IOP evaluation. 
IOP measurements were performed by three well-trained masked observers who were unaware of the treatment assignments; their agreement was previously tested on a pilot sample of 15 patients, resulting in an intraclass correlation coefficient of 0.97 and 0.99 for Tonopen and Goldmann tonometry, respectively. 
A comprehensive ocular and systemic examination was performed at baseline and at the conclusion of each phase of the trial, and any ocular or systemic adverse events were noted.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5694185f-4941-4d9d-a941-04122fbf9ee3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16738-0</funderId>
      <contactId>Contact54696_16738</contactId>
      <sponsorId>Sponsor53252</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54696_16738">
    <title>Prof</title>
    <forename>Luciano</forename>
    <surname>Quaranta</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centro per lo studio del glaucoma
Piazzale Spedali Civili 1 </address>
      <city>Brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53252">
    <organisation>Clinica Oculistica (Italy)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Piazzale Spedali Civili 1 </address>
      <city>brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16738-0">
    <name>Ministry of Education, University and Research  (Ministero dell&#146;Universit√† e della Ricerca; MIUR) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-04T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">81465865</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of electrical neurostimulation on collateral perfusion during acute coronary occlusion</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Neurostimulation can improve collateral perfusion measured as a coronary wedge pressure (Pw)/aortic pressure (Pa) ratio, during acute coronary occlusion.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was collateral perfusion, the Pw/Pa ratio. This was measured during a one-minute balloon inflation during PCI. The Pw/Pa ratio was measured in each patient during two ischaemic episodes. To compare the Pw/Pa ratio with and without electrical neurostimulation, the Pw/Pa ratio is measured intracoronary, using a pressure wire.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81465865</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="37603721-b3d4-43a5-8a65-17a38c12c6b8">
	  <name>Thorax Centre</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 GZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with stable angina
2. Evidence of myocardial ischaemia
3. Planned for elective Percutaneous Coronary Intervention (PCI)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Recent myocardial infarction
2. Prior coronary artery bypass grafting
3. Undtable angina
4. Conduction disturbances
5. Pacemaker
6. Internal cardio-defibrillator</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Angina pectoris, electrical neurostimulation, coronary collaterals, angioplasty</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischaemic heart diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention was electrical neurostimulation, during five minutes before and during the one-minute ischaemic episode. Within a patient we measured during the one-minute ischaemic episode the collateral perfusion, with and without electrical neurostimulation. The ischaemic episode was established by balloon inflation during elective PCI.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4909579f-7266-424f-9850-f719318cfec2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16565-0</funderId>
      <contactId>Contact54523_16565</contactId>
      <sponsorId>Sponsor53078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54523_16565">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>de Vries</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thorax Centre 
University Medical Centre Groningen
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 GZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.de.vries@thorax.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53078">
    <organisation>University Medical Centre Groningen (UMCG) (The Netherlands)</organisation>
    <website>http://www.umcg.nl/azg/nl/english/azg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Thorax Centre
Department of Cardiology</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16565-0">
    <name>University Medical Centre Groningen (UMCG) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-02T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-20T00:00:00.000Z">87589121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving patient reassurance through an early intervention prior to exercise stress testing</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing information about normal findings prior to a exercise stress test will improve reassurance and reduce anxiety about symptoms following the investigation in patients with a negative test result.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Patients&#146; reported reassurance.
2. Levels of worry about their health and belief that something is seriously wrong with their heart, measured immediately following the test and at one month following testing.</primaryOutcome>
      <secondaryOutcome>Complaints of chest pain and whether continuing to take cardiac medication.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by New Zealand Ministry of Health Ethics Committee (ref AKY/04/05/121) on 21 May, 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87589121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45f157c1-a7e3-4ba6-9321-948f83971b77">
	  <name>Department of Psychological Medicine</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients referred for exercise stress test with negative findings</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Previously diagnosed cardiac pathology
3. No symptoms of chest pain
4. Undertaking the stress exercise test as part of a pre-surgical medical examination
5. Positive exercise stress test</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Symptoms of chest pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Chest pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: standard information. 
Group two: a pamphlet explaining the function and meaning of negative results from the test.
Group three: the pamphlet and a brief discussion about what normal results of the test mean.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6dcdd103-4dee-4480-a562-3ca5fdf0bb2f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15754-0</funderId>
      <contactId>Contact53692_15754</contactId>
      <sponsorId>Sponsor52246</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53692_15754">
    <title>Prof</title>
    <forename>Keith</forename>
    <surname>Petrie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychological Medicine
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52246">
    <organisation>University of Auckland (New Zealand)</organisation>
    <website>http://www.auckland.ac.nz/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9654.e</gridId>
    <rorId>https://ror.org/03b94tp07</rorId>
  </sponsor>
  <funder id="Funder15754-0">
    <name>University of Auckland (New Zealand)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001537</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-26T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-07-03T00:00:00.000Z">27844532</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Correction of acidosis in hemodialysis patients. Effects on protein metabolism, investigated by tracer technique and messenger-ribonucleic acid determination for ubuquitin and proteasome subunits.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Metabolic acidosis stimulates muscle protein breakdown, correction of acidosis results in decreased protein breakdown.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle protein turnover</primaryOutcome>
      <secondaryOutcome>1. messenger-Ribonucleic Acid (mRNA) for ubuquitin and proteasome subunits
2. Plasma and muscle intracellular amino acid concentrations
3. Serum albumin</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of Karolinska Institute at Huddinge University Hospital on 11/01/1993, reference number: 196/96</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27844532</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, crossover design</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0e0d4dda-cd65-46c3-be58-d66235aa6a8d">
	  <name>Karolinska University Hospital</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-171 76</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable hemodialysis patients
2. &gt;18 Years of age</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Clinically obvious malnutrition
2. Ongoing infection
3. Diabetes mellitus
4. Untreated congestive heart failure
5. Treatment with corticosteroids or other immunosuppressive agents</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage renal failure</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Adjustments of acid-base balance - in each patient, protein turnover will be measured twice, at a standard bicarbonate concentration of &lt;19 mmol/l and &gt;25 mmol/l respectively, with an interval between the two measurements (random order) of 3-4 weeks. The acid-base status will be altered by adjusting the dose of bicarbonate (oral and/or via dialysis) and protein turnover will be measured when the predialysis bicarbonate level have been low or normal for at least one week.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e1ffa7b4-9243-4ab4-b743-5231026d1d16" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14950-0</funderId>
      <funderId>Funder14950-1</funderId>
      <funderId>Funder14950-2</funderId>
      <funderId>Funder14950-3</funderId>
      <contactId>Contact52751_14950</contactId>
      <sponsorId>Sponsor51290</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52751_14950">
    <title>Dr</title>
    <forename>Erland</forename>
    <surname>L√∂fberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Karolinska University Hospital
Department of Renal Medicine
Solna</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-171 76</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 1773768</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erland.lofberg@karolinska.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51290">
    <organisation>Karolinska University Hospital (Sweden)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Clinical Science
Karolinska Institute
Huddinge</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-14186</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 8582656</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anders.alvestrand@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.24381.3c</gridId>
    <rorId>https://ror.org/00m8d6786</rorId>
  </sponsor>
  <funder id="Funder14950-0">
    <name>Swedish Medical Research Council (ref: 11243 and 04210)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-1">
    <name>Gambro AB</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-2">
    <name>Baxter Inc.</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-3">
    <name>U.S. National Institutes of Health (R01 DK37175)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-04-24T00:00:00.000Z">27914471</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the efficacy and effectiveness of dihydroartemisinin-piperaquine and artesunate-mefloquine in the treatment of falciparum malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Non-inferiority of efficacy and effectiveness of dihydroartemisinin-piperaquine compared to mefloquine-artesunate for the treatment of uncomplicated falciparum malaria in adults and children in western Myanmar.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Polymerase chain reaction (PCR) adjusted parasitological failure rates by day 42</primaryOutcome>
      <secondaryOutcome>1. Vivax appearances
2. Gametocytaemia (person gametocyte weeks between day 0 and 42)
3. Whole blood piperaquine levels at day 7
4. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Doctors Without Borders (Medecins sans Frontieres [MSF]) Ethical Review Board on 05/12/2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27914471</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An open randomised comparison</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Myanmar</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1363b470-5dde-430b-bdc0-0e1ce5679d5c">
	  <name>Thanlwin Road 62 A</name>
	  <address/>
	  <city>Yangon</city>
	  <state/>
	  <country>Myanmar</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with fever (axillary temperature &gt;37.5¬∞C), or a history of fever within 48 hours
2. Confirmed falciparum malaria (mixed infection P. falciparum with P. vivax and/or P. malariae were included), with more than 500 but less than 100,000 asexual parasites per ml</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>640</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>640</totalTarget>
      <exclusion>1. Signs of severe and complicated malaria
2. Children below one-year-old
3. Pregnant women
4. Patients with a history of taking mefloquine during the previous two months
5. Patients taken any other antimalarial drugs in the previous 48 hours
6. Patients with a history of psychiatric diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falciparum malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Falciparum malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of two different treatment regimes: dihydroartemisinin-piperaquine and mefloquine-artesunate. Both treatment regimes were given observed or not observed; total of four study groups.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dihydroartemisinin-piperaquine and artesunate-mefloquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50837bb6-41aa-45f4-8f02-fa9d7daa68de" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14551-0</funderId>
      <contactId>Contact52284_14551</contactId>
      <sponsorId>Sponsor50768</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52284_14551">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Smithuis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thanlwin Road 62 A</address>
      <city>Yangon</city>
      <country>Myanmar</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+95 1 534679</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msfh_yangon@mptmail.net.mm</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50768">
    <organisation>Doctors Without Borders (Medecins sans Frontieres [MSF]) (The Netherlands)</organisation>
    <website>http://www.artsenzondergrenzen.nl</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Plantage Middenlaan 14</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1018DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5208700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@amsterdam.msf.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452780.c</gridId>
    <rorId>https://ror.org/04237en35</rorId>
  </sponsor>
  <funder id="Funder14551-0">
    <name>Internally funded by Doctors Without Borders (Artsen zonder Grenzen MSF) (Holland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-01-18T00:00:00.000Z">46117662</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the equivalence of ceftriane plus azithromycin or doxycycline for the treatment of pelvic inflammatory disease</title>
      <scientificTitle/>
      <acronym>DAZ</acronym>
      <studyHypothesis>1 g of azithromycin once a week for two weeks is equivalent to 14 days of 200 mg doxycycline per day.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome for the trial is clinical cure, defined as improvement or absence of the initial pain at day 14 compared to baseline.</primaryOutcome>
      <secondaryOutcome>1. A clinical cure, defined as 70% or greater reduction in the total tenderness score at day 14 compared to baseline
2. Histological cure defined as absence of plasma cell per X120 field in the endometrial stroma and &lt;5 neutrophils per X400 field in the endometrial surface
3. Absence of Neisseria gonorrhea and Chlamydia trachomatis on endometrial samples on day 30 by PCR techniques</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Hospital de Clinicas de Porto Alegre (HCPA) Institutional Review Board (ref: IRB0000921)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46117662</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>03-006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized double-blinded placebo trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="60d73c57-815a-413d-8764-5f05f2e6165e">
	  <name>Rua Ramiro Barcelos, 2350/1125</name>
	  <address/>
	  <city>Porto Alegre</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>90035-003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A history of pelvic discomfort for a period of 30 days or less
2. Findings of pelvic organ tenderness (uterine or adnexal) on bimanual examination
3. Leukorrhea and/or mucopurulent cervicitis and/or untreated known positive gonococcal or chlamydial cervicitis</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>112</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>112</totalTarget>
      <exclusion>1. Current pregnancy as demonstrated by beta-Human Chorionic Gonadotrophin (HCG) or ultrasonography
2. Inability to tolerate an outpatient oral regimen as demonstrated by the vomiting of eight ounces of water one hour after taking 10 mg of metoclopramide
3. Presence of tubo-ovarian abscess, appendicitis or hemorrhagic ovarian cysts confirmed by ultrasound or laparoscopy
4. Pelvic pain over 30 days duration
5. Allergy to ceftriaxone, azithromycin or doxycycline
6. Antimicrobial therapy within seven days of recruitment
7. Delivery, abortion or gynecological surgery within 30 days
8. Prior hysterectomy or bilateral salpingectomy
9. Homelessness
10. Fever
11. Abdominal rebound tenderness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pelvic inflammatory disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Pelvic inflammatory disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Eligible patients were invited to participate in the doxycycline azithromycin protocol (DAZ). After giving written consent, a standardized interview, examination and specimen collection techniques were taken. Only three researchers will perform the physical exams. Whenever possible, the researcher that performed the first clinical examination on the first visit also did follow up on that patient.
A standardized screening examination, including a visual pain scale (0-10), and the McCormick modified pain scale was performed in the same sequence by the three researchers. A complete blood count, endometrial biopsy, urinalysis, and erythrocyte sedimentation rate will be performed on the first visit.
Endometrial samples will be divided into two equal amounts. One will be snap frozen in liquid nitrogen for Polymerase Chain Reaction (PCR) analysis and the other will be fixed in formaldehyde for histological analysis.
After the initial interview, the patient will receive a parenteral 250 mg ceftriaxone injection and will be randomly allocated to one of two treatment groups.

Randomization and treatment:
A restricted randomization sequence list was generated by computer, and was kept concealed from the researcher until the moment of assignment. We will consider subjects in blocks of four at a time to create the allocation sequence. After the patient is enrolled in the protocol, she will be blindly assigned to a coded treatment, either 14 days doxycycline or 1 g of azithromycin per week for two weeks. To avoid bias, the medication will be manipulated by the hospital pharmacy and will be put in identically coded blisters (treatment A, treatment B). To confirm compliance, a treatment of just seven days will be given to the patient, forcing her to return in seven days to receive the rest of the treatment. Because of the difference in the amount of capsules in each treatment, the azithromycin blister was filled up with placebo.
In the first visit, the patient will receive 250 mg intramuscular ceftriaxone and a blister for seven days treatment. The first dose of the medication (1 g of azythromycin, or 200 mg of doxycycline) will be taken in front of the physician. She will receive a leaflet and instructions of how she should take the rest of the medication. Special attention was taken about warning against taking the medication on an empty stomach, using analgesics, and abstaining from sexual intercourse until the treatment was completed. All women will be advised to have their partner treated with 1 g of azithromycin.

Endometrial biopsy and definition of endometritis:
The endometrial biopsy was performed at the office using a Karman plastic curette (MedGyn Products Inc., Lombard, IL, USA). Histopathological endometritis was defined by the presence of  ‚â•1 plasma cell per X120 field in the endometrial stroma plus ‚â•5 neutrophils per X400 field in the endometrial surface.
PCR techniques will be used to investigate the presence of Neisseria gonorrhea and Chlamydia trachomatis in the endometrial samples.

Follow-up and adherence:
Participants will be monitored with in-person visits at 2, 7, 14 and 30 days. In each visit, the gynecological examination and the assessment of the pain will be registered. On day 7, the patient will return the first blister and receive the second one. Again, the first dose will be taken in front of the physician. On day 14, she will return the second blister. Adherence will be checked by absence of capsules in each blister. On day 30, another endometrial biopsy will be performed to measure histological cure and blood tests will be repeated.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftriane, azithromycin and doxycycline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17601896 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="46de5042-8aab-407e-824e-7cd7f0713018" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17601896"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14275-0</funderId>
      <contactId>Contact52016_14275</contactId>
      <sponsorId>Sponsor50476</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52016_14275">
    <title>Prof</title>
    <forename>Ricardo</forename>
    <surname>Savaris</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Ramiro Barcelos, 2350/1125</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rsavaris@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50476">
    <organisation>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</organisation>
    <website>http://www.hcpa.ufrgs.br/default.asp?sacao=Institucional&amp;sPagina=96&amp;gSysCodigoConexao=</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua Ramiro Barcelos 2350/2
Andar</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l-cpesquisas@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.470786.a</gridId>
    <rorId>https://ror.org/040y74d88</rorId>
  </sponsor>
  <funder id="Funder14275-0">
    <name>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">12757724</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Creating and maintaining functional residual capacity in preterm neonates with Respiratory Distress Syndrome (RDS)</title>
      <scientificTitle/>
      <acronym>EFURCI</acronym>
      <studyHypothesis>A sustained inflation with a mechanical device and early nasal continuous positive airway pressure is a more effective management strategy for RDS in preterm infants than conventional intervention with a self-inflating mask and bag, and reduces the requirement for mechanical ventilation and surfactant treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Need of endotracheal intubation within 3 days after birth.</primaryOutcome>
      <secondaryOutcome>1. Death
2. Bronchopulmonary Dysplasia (BPD)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12757724</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="14ef1c34-e6e3-44e6-8f6b-968666e96b35">
	  <name>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Preterm neonates
2. Gestational age range 25 - 32 weeks (more than 24 weeks and 6 days and not more than 32 weeks and 6 days)</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Antenatal diagnosed congenital anomalies of the cardio or respiratory system or anomalies incompatible with survival.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory Distress Syndrome, Preterm neonates</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory Distress Syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Resuscitation at birth when necessary:
Group A: Prolonged inflation of 10 seconds with a mechanical device (Neopuff t-piece resuscitator) and early CPAP treatment.
Group B: Inflation with self-inflating mask and bag conform international resuscitation guidelines.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17671058 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10d2d3c0-fcd0-4102-b651-126e23bb21fb" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17671058"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14353-0</funderId>
      <contactId>Contact52101_14353</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52101_14353">
    <title>Dr</title>
    <forename>Arjan B.</forename>
    <surname>Pas, te</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5262909</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.b.te_pas@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14353-0">
    <name>Leiden University Medical Centre  (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-11-03T00:00:00.000Z">34123170</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing tuberculosis case detection and reducing gender disparities through sputum submission instructions: a randomised controlled trial in Pakistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Giving women instructions on how to provide sputum samples will increase the yield of smear positive tuberculosis diagnoses in a chest clinic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was specimen smear-positivity.</primaryOutcome>
      <secondaryOutcome>The secondary outcome, specimen quality, was determined by visual assessment of specimens and microscopic assessment of Ziehl-Neelsen (ZN) stained smears, using a modification of the rating system of Bartlett.
Specimens with a purulent/mucoid/blood-stained visual appearance and/or containing polymorphoneutrophils (PMNs) on microscopic inspection were designated &#145;sputum&#146;.
Specimens with a clear/watery appearance containing squamous epithelial cells, but no PMNs were designated &#145;saliva&#146;.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34123170</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Pakistan</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="63ef6448-7235-4481-929c-bcfb54678d7b">
	  <name>Keppel Street</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>New male and female tuberculosis (TB) suspects, who were referred by TB centre physicians for initial diagnostic sputum testing, were eligible to participate in the trial. According to the National Tuberculosis Control programme guidelines, the criteria for enrolment were:
1. History of a cough for &gt;3 weeks and/or fever for 1 month
2. Blood in sputum
3. Night sweats
4. Weight loss
5. Loss of appetite</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2600</totalTarget>
      <exclusion>1. Age over 75 or below 14 years
2. History of TB diagnosis or treatment
3. Intake of oral steroids in the 3 months leading up to presentation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients in the intervention arm were referred to a designated room at the TB centre where they received guidance from a female health worker who was trained by the researcher and a senior TB control officer to provide sputum submission instructions. The female health worker was not involved in recruitment or randomisation. The following points were explained in detail to patients:
1. The importance of submitting sputum rather than saliva, and a description of visual difference between the two
2. The technique that should be used to produce a good sputum specimen (&#145;take three deep breaths, followed by a deep cough to bring up sputum from your lungs&#146;)
3. The necessity of filling at least one-quarter of the container (5 ml), shown by pointing out the required level on a demonstration container
4. The importance of providing one &#145;spot&#146; specimen and returning the next day with another specimen which has been expectorated on awakening that morning

Following instructions, which lasted between 2-3 min, patients in the intervention group were directed to the laboratory to obtain sputum submission containers.

Control group: usual procedure</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17560448 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3f202d0d-84ce-4eb0-9e17-4f5975cbb5c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17560448"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13699-0</funderId>
      <contactId>Contact51373_13699</contactId>
      <sponsorId>Sponsor49777</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51373_13699">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Godfrey-Faussett</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Keppel Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pgf@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49777">
    <organisation>London School of Hygiene and Tropical Medicine (UK)</organisation>
    <website>http://www.lshtm.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Keppel Street</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8991.9</gridId>
    <rorId>https://ror.org/00a0jsq62</rorId>
  </sponsor>
  <funder id="Funder13699-0">
    <name>Department for International Development (DFID) (UK) - Knowledge Programme on Tuberculosis</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-10T00:00:00.000Z">98554309</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of vitamin A dosing schedules in infancy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Early high-dose vitamin A supplementation of mothers and infants improves vitamin A status and protects against mucosal infections, growth faltering and illness compared to the standard World Health Organisation (WHO) regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Vitamin A status in mothers and infants
2. Heliobacter pylori infection in infants
3. Nasopharyngeal pneumococcal carriage in mothers and infants
4. Gut permeability in infants assessed by Dual Pugar Permeability Test (DSPT)</primaryOutcome>
      <secondaryOutcome>1. Infant growth
2. Infant morbidity
3. Breast milk sodium-potassium ratios
4. Breast-milk oligosaccharides</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98554309</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Gambia</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b368821c-109c-4084-8d95-c9e6ad2f99dd">
	  <name>MRC International Nutrition Group</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consenting mothers and new born infants in six villages in the West Kiang region of The Gambia.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>220</totalTarget>
      <exclusion>1. Congenital defects
2. Birthweight under 2200 g</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin A supplementation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Early high dose Vitamin A schedule versus standard WHO schedule.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17586304 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="34fa6ac7-f9ea-40a0-9f2c-62582a95f12e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17586304"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13439-0</funderId>
      <contactId>Contact51085_13439</contactId>
      <sponsorId>Sponsor49481</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51085_13439">
    <title>Prof</title>
    <forename>Andrew</forename>
    <surname>Prentice</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC International Nutrition Group
London School of Hygiene and Tropical Medicine</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7958 8140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.prentice@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49481">
    <organisation>Medical Research Council (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W1N 4AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">corporate@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.14105.31</gridId>
    <rorId>https://ror.org/03x94j517</rorId>
  </sponsor>
  <funder id="Funder13439-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">97327133</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect on participants, and experience of a psychological group therapy programme for women with the Mayer-Rokitansky-Kuster-Hauser syndrome: a randomised controlled treatment trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>How does psychological group therapy affect women with Mayer-Rokitansky-Kuster-Hauser (MKHR) syndrome?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the effect of a psychological group therapy programme on women with MRKH</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97327133</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0016152852</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-16T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ef91d190-eb32-460e-985f-0a8d042d6d1b">
	  <name>National Centre for Adolescent and Adult Women with Congenital Abnorma</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0HS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women affected with MRKH</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-16T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mayer-Rokitansky-Kuster-Hauser Syndrome</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Mayer-Rokitansky-Kuster-Hauser Syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised controlled psychological group therapy trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17584749/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="299704a9-953b-48b8-b99e-1747cdca09c5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17584749/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13871-0</funderId>
      <funderId>Funder13871-1</funderId>
      <contactId>Contact51749_13871</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51749_13871">
    <title>Ms</title>
    <forename>Jacoline</forename>
    <surname>Heller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Centre for Adolescent and Adult Women with Congenital Abnorma
Queen Charlottes
Queen Charlottes
Hammersmith Hospital, Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0HS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 8383 5363</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k1m2erley@aol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13871-0">
    <name>Hammersmith Hospital NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13871-1">
    <name>NHS R&amp;D Support (UK) (Funding 2004/05)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-21T00:00:00.000Z">03012627</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Variations of Internet-assisted cognitive behaviour therapy: a randomized community trial of MoodGYM users</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To investigate whether the length of the MoodGYM program (i.e. the number and combination of modules undertaken by the user) is related to treatment outcome, and which sub-components of the program are associated with anxiety and depression reduction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The change in participants' symptoms of depression and anxiety after completing their version of the MoodGYM program.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.moodgym.anu.edu.au</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 13/08/2007: Approved by the Australian National University Human Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03012627</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d81250b7-dc60-4649-b594-761f488d3afa">
	  <name>Centre for Mental Health Research</name>
	  <address/>
	  <city>Canberra</city>
	  <state/>
	  <country>Australia</country>
	  <zip>0200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants will be individuals who register on the MoodGYM website and who consent to be randomised to a condition in the trial.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500</totalTarget>
      <exclusion>Individuals who register on the MoodGYM website and who do not consent to participation in the trial. These individuals will be directed to the 'full' MoodGYM site, rather than a version of the site being evaluated in this trial. Individuals who consent to participation in the research project but who opt to choose their treatment condition are also not included in the randomised controlled trial (RCT).</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The MoodGYM website, an evidence-based depression prevention program. Six versions of the website will be evaluated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16938144 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="efa9f103-4ba4-4beb-8814-1ef82ccf0885" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16938144"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13386-0</funderId>
      <contactId>Contact51015_13386</contactId>
      <sponsorId>Sponsor49407</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51015_13386">
    <title>Prof</title>
    <forename>Helen</forename>
    <surname>Christensen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Mental Health Research
Australian National University</address>
      <city>Canberra</city>
      <country>Australia</country>
      <zip>0200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)261258409</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">helen.christensen@anu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49407">
    <organisation>Australian National University - Centre for Mental Health Research</organisation>
    <website>http://www.anu.edu.au/cmhr</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Canberra</city>
      <country>Australia</country>
      <zip>0200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)261258409</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">helen.christensen@anu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1001.0</gridId>
    <rorId>https://ror.org/019wvm592</rorId>
  </sponsor>
  <funder id="Funder13386-0">
    <name>Australian National Health and Medical Research Council (NHMRC) Program Grant to the Centre for Mental Health Research</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-25T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-14T00:00:00.000Z">15819627</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sucrose as Procedural Analgesia for Infants Receiving Venipuncture in a Pediatric Emergency Department</title>
      <scientificTitle/>
      <acronym>SWEET Study</acronym>
      <studyHypothesis>Pain scores will be significantly reduced for infants who either recieve sucrose, pacifier or both prior to venipuncture as compared to placebo</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Score on the Faces Legs Arms Crying and Consolability (FLACC) Scale</primaryOutcome>
      <secondaryOutcome>Crying Time, Heart Rate</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15819627</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="585505da-71c1-4959-92ba-9057bc76308d">
	  <name>Room 7217B, Second Floor</name>
	  <address/>
	  <city>Edmonton,  Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2J3</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Any infant 0-6 months requiring venipuncture as part of their emergency department management</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="0.0"/>
      <upperAgeLimit unit="Months" value="6.0"/>
      <gender>Both</gender>
      <targetEnrolment>132</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>132</totalTarget>
      <exclusion>Infants deemed too critically ill or otherwise ineligible at the discretion of the attending physician</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomly assigned to one of four groups as follows:
a. Sucrose orally (PO)
b. Sucrose PO &amp; pacifier
c. Placebo PO
d. Placebo PO &amp; pacifier</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17640375 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="13476211-8c7f-478b-9ae3-638513a342aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17640375"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13361-0</funderId>
      <contactId>Contact50984_13361</contactId>
      <sponsorId>Sponsor49376</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50984_13361">
    <title>Dr</title>
    <forename>Sarah</forename>
    <surname>Curtis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Room 7217B, Second Floor
Aberhart Centre One</address>
      <city>Edmonton,  Alberta</city>
      <country>Canada</country>
      <zip>T6G 2J3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49376">
    <organisation>University of Alberta, Department of Pediatrics (Canada)</organisation>
    <website>http://www.med.ualberta.ca/pediatrics/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Aberhart Centre One
11402 University Avenue</address>
      <city>Edmonton, Alberta</city>
      <country>Canada</country>
      <zip>T6G 2J3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17089.37</gridId>
    <rorId>https://ror.org/0160cpw27</rorId>
  </sponsor>
  <funder id="Funder13361-0">
    <name>Department of Pediatrics, University of Alberta</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-04-26T00:00:00.000Z">31571714</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial to evaluate the effects of didgeridoo playing on snoring</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Epworth scale
2. Pittsburgh Sleep Quality Index
3. 36-item Short Form health survey (SF-36)
4. Proxy evaluation
5. Apnoea-hypopnea-index</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31571714</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9a103cc9-e68f-4fd7-87ce-f851962c2ccf">
	  <name>Horten Centre</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>30 patients of at least 18 years of age with snoring and apnoea-hypopnea-index 15-30.</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Treatment for sleep apnoea (e.g. with continuous positive airway pressure [CPAP])
2. Body Mass Index greater than 30
3. More than seven drinks per week
4. Regular intake of psychostimulating drugs and current or planned weight reduction intervention</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Snoring and apnoea-hypopnea-index 15-30</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Breathing difficulties</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Playing Didgeridoo for a period of four months, at least five times a week. Regular instructions by professional Didgeridoo-Teacher.
Control group: No Didgeridoo playing for a period of four months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377643 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="85e7602e-dd18-4d48-aafd-848d61e363f0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377643"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12909-0</funderId>
      <funderId>Funder12909-1</funderId>
      <funderId>Funder12909-2</funderId>
      <contactId>Contact50419_12909</contactId>
      <sponsorId>Sponsor48789</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50419_12909">
    <title>Dr</title>
    <forename>Milo</forename>
    <surname>Puhan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Horten Centre
University Hospital
Postfach Nord</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 1 255 87 09</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">milo.puhan@evimed.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48789">
    <organisation>Z√ºrcher H√∂henklinik Wald (Switzerland)</organisation>
    <website>http://www.zhw.ch/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Faltigberg-Wald</city>
      <country>Switzerland</country>
      <zip>8639</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zhw.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder12909-0">
    <name>Z√ºrcher H√∂henklinik Wald (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12909-1">
    <name>Z√ºrcher Lungenliga (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12909-2">
    <name>Praxis Alex Suarez (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-04-26T00:00:00.000Z">67999735</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of support on intra-abdominal pressure, hepatic kinetics of indocyanine green and extravascular lung water during Prone Positioning (PP) in ARDS patients: a randomised crossover study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the present study was to investigate whether the evolution of Intra-Abdominal Pressure (IAP), liver function assessed by the Plasma Disappearance Rate of Indocyanine Green (PDRICG) and extravascular lung water is related to the type of support during PP. We therefore prospectively compared, in a population of medical-Acute Respiratory Distress Syndrome (ARDS) patients, the effects of an air-cushioned mattress and a conventional foam mattress during PP.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Intra-Abdominal Pressure (IAP)
2. Plasma Disappearance Rate of Indocyanine Green (PDRICG)
3. Extravascular Lung Water (EVLW)
4. Partial Pressure of Oxygen in Arterial Blood (PaO2)/Fraction of Inspired Oxygen (FiO2) ratio
5. Central Venous Pressure (CVP)
6. Mean pulmonary arterial pressure
7. Pulmonary artery occlusion pressure</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67999735</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02ff6869-3f33-4b29-8452-ffe829515ec5">
	  <name>D√©partement d'Anesth√©sie R√©animation</name>
	  <address/>
	  <city>Marseille</city>
	  <state/>
	  <country>France</country>
	  <zip>13009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Twenty consecutive patients with ARDS were included and turned prone in the medical intensive care unit of Sainte Marguerite University Hospital in Marseille, France. Patients were prospectively included in this study after obtaining written informed consent from the next of kin. The study design was approved by the Comit√© Consultatif de Protection des Personnes dans la Recherche Biom√©dicale of Marseille. ARDS was defined in accordance with the recommendations of the American/European Consensus Conference.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients with unstable cardiovascular function, cerebral injury or unstable spinal fractures, patients subjected to major abdominal surgery and patients with a history of neuromuscular disease were excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Respiratory Distress Syndrome (ARDS)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Baseline measurements were performed in the supine position after one hour of steady-state conventional mechanical ventilation. Then the following two periods of PP were randomised: 
1. 6 hours of PP on the moulded foam mattress
2. 6 hours of PP on the air-cushioned mattress

A period of 18 hours in the supine position separated the two periods in the prone position. Each patient was his or her own control. Measurements were achieved in the supine position, after 1 and 6 hours of PP.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15987398 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f8bb5111-7677-45b4-9c00-51ef3a45e216" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15987398"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13016-0</funderId>
      <contactId>Contact50545_13016</contactId>
      <sponsorId>Sponsor48923</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50545_13016">
    <title>Dr</title>
    <forename>Pierre</forename>
    <surname>Michelet</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>D√©partement d'Anesth√©sie R√©animation
Sainte Marguerite Hospital</address>
      <city>Marseille</city>
      <country>France</country>
      <zip>13009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pierre.michelet@mail.ap-hm.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48923">
    <organisation>Sainte Marguerite Hospital (France)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Marseille</city>
      <country>France</country>
      <zip>13009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pierre.michelet@mail.ap-hm.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414438.e</gridId>
    <rorId>https://ror.org/0338wkj94</rorId>
  </sponsor>
  <funder id="Funder13016-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-21T00:00:00.000Z">61514736</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).</title>
      <scientificTitle/>
      <acronym>UCLA PRIME MD-2</acronym>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61514736</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1c91592c-e440-499b-95e3-0df87d1ec828">
	  <name>924 Westwood Blvd Suite 300</name>
	  <address/>
	  <city>Los Angeles, CA</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>90024-2924</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>ED patients who present with a somatic (non-psychiatric) complaint that is of long duration, is chronic, or is not of a severity to warrant emergency care.
Resident physicians in Emergency Medicine and their faculty.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration.</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression, anxiety and other psychiatric conditions</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients take the computerized PRIME-MD in the ED waiting room.  They are randomized to three groups: PRIME-MD results shared with no one, shared with the patient only, or shared with the patient and the treating ED physician.
Low cost/no cost psychiatric referral sheet made available in the ED.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15882462 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bd714197-02e3-42f2-abe8-97b1e80795a4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15882462"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12897-0</funderId>
      <contactId>Contact50405_12897</contactId>
      <sponsorId>Sponsor48774</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50405_12897">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Schriger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>924 Westwood Blvd Suite 300</address>
      <city>Los Angeles, CA</city>
      <country>United States of America</country>
      <zip>90024-2924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 310 794 0593</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">schriger@ucla.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48774">
    <organisation>University of California, Los Angeles (UCLA) (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>924 Westwood Blvd Suite 300</address>
      <city>Los Angeles, CA</city>
      <country>United States of America</country>
      <zip>90024 2924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.19006.3e</gridId>
    <rorId>https://ror.org/046rm7j60</rorId>
  </sponsor>
  <funder id="Funder12897-0">
    <name>The Pfizer Corporation provided a $60,000 gift (not grant) in support of this research.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-01-19T00:00:00.000Z">24484328</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Half versus full suction drainage after mastectomy for breast cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24484328</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="390cd09a-ac9b-4164-8451-dc3bc6243a01">
	  <name>DII/131, West Kidwai Nagar</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110023</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>85 fine needle aspiration cytology (FNAC) proven cases of locally advanced breast cancer were randomised into two groups. The groups were comparable in respect of age, weight and type of operation i.e. modified radical mastectomy (MRM)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>85</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>85</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 50 patients randomised to full vacuum suction (pressure = 700 g/m^2)
Group 2: 35 patients randomised to half vacuum suction (pressure = 350 g/m^2)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15676064 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10cab4b5-b5a4-4d4a-a82d-28f3e713ccd0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-01-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15676064"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12859-0</funderId>
      <funderId>Funder12859-1</funderId>
      <funderId>Funder12859-2</funderId>
      <contactId>Contact50349_12859</contactId>
      <sponsorId>Sponsor48719</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50349_12859">
    <title>Dr</title>
    <forename/>
    <surname>Chintamani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>DII/131, West Kidwai Nagar </address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110023</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)98 10064920</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chintamani7@rediffmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48719">
    <organisation>Safdarjang Hospital - Vardhman Mahavir Medical College and Indian Council of Medical Research (India)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110033</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)11 26268336 104</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chintamani@doctor.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416888.b</gridId>
    <rorId>https://ror.org/03zj0ps89</rorId>
  </sponsor>
  <funder id="Funder12859-0">
    <name>Institutions controlled by the government:</name>
    <fundRef/>
  </funder>
  <funder id="Funder12859-1">
    <name>Vardhman Mahavir Medical College, Safdarjang Hospital (India)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12859-2">
    <name>Indian Council Of Medical Research (India)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001411</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-11-30T00:00:00.000Z">21676344</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21676344</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b02bc080-b9e9-47ac-84cc-3de1bc7fbbb6">
	  <name>Department of Medicine</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pulmonary disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>N-acetylcysteine 600 mg twice daily or matching placebo.
All participants received standard care including oxygen, nebulised salbutamol, oral prednisone and antibiotics (if indicated).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15581425 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7dc28042-3969-4ac2-be6e-d3d75a7f5103" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15581425"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12815-0</funderId>
      <contactId>Contact50288_12815</contactId>
      <sponsorId>Sponsor48659</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50288_12815">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Black</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medicine
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 93737599 ext 89797</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pn.black@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48659">
    <organisation>Health Research Council of New Zealand</organisation>
    <website>http://www.hrc.govt.nz/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 5541
Wellesley St</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 93035200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hrc.govt.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452999.a</gridId>
    <rorId>https://ror.org/00zbf3d93</rorId>
  </sponsor>
  <funder id="Funder12815-0">
    <name>Health Research Council of New Zealand (ref: HRC 01/206)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001505</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-11-30T00:00:00.000Z">40455708</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial comparing digital and live lecture formats</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40455708</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="42293375-1a1b-4aed-9e08-2ec242e9217f">
	  <name>A-202 E Fee Hall</name>
	  <address/>
	  <city>E Lansing, MI</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>48840</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Medical students</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impact on learning</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Digital versus live lectures</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569389 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b3baca68-2e17-41ec-8343-7cfb934ed43e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569389"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11234-0</funderId>
      <contactId>Contact41672_11234</contactId>
      <sponsorId>Sponsor39417</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41672_11234">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Solomon</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>A-202 E Fee Hall
MSU</address>
      <city>E Lansing, MI</city>
      <country>United States of America</country>
      <zip>48840</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dsolomon@msu.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39417">
    <organisation>Michigan State University (USA)</organisation>
    <website>http://www.msu.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>E Lansing, MI</city>
      <country>United States of America</country>
      <zip>48824</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dsolomon@msu.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.17088.36</gridId>
    <rorId>https://ror.org/05hs6h993</rorId>
  </sponsor>
  <funder id="Funder11234-0">
    <name>Division of Medicine, Bureau of Health Professions, Health Services and Resources Administration (USA) (grant no.: 1 D16 HP 00119 01)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-11-29T00:00:00.000Z">70292892</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of Chinese herbal recipe versus diclofenac in symptomatic treatment of 
osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70292892</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>67/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Thailand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1e7b8976-8a5b-40dc-ba9d-b6e1788578e4">
	  <name>Department of Pharmacology</name>
	  <address/>
	  <city>Chiang Mai</city>
	  <state/>
	  <country>Thailand</country>
	  <zip>50200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients who had been suffering from unilateral or bilateral OA of the knee according to the criteria of the American College of Rheumatology for more than 3 months</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: Chinese herbal medicine (6 capsules after meal, 3 times a day) plus placebo of diclofenac (1 capsule after meal, 3 times a day)
2nd Group: Placebo of Chinese herbal medicine (6 capsules after meal, 3 times a day) plus diclofenac (1 capsule after meal, 3 times a day)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Chinese herbal recipe versus diclofenac</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15588333 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="26a0b4d9-891b-490c-8dd0-db7560776299" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15588333"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12811-0</funderId>
      <contactId>Contact50284_12811</contactId>
      <sponsorId>Sponsor48655</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50284_12811">
    <title>Dr</title>
    <forename>Supanimit</forename>
    <surname>Teekachunhatean</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacology
Faculty of Medicine
Chiang Mai University</address>
      <city>Chiang Mai</city>
      <country>Thailand</country>
      <zip>50200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steekach@mail.med.cmu.ac.th</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48655">
    <organisation>Chiang Mai University - Faculty of Medicine (Thailand)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Chiang Mai</city>
      <country>Thailand</country>
      <zip>50200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">nimit@mail.med.cmu.ac.th</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7132.7</gridId>
    <rorId>https://ror.org/05m2fqn25</rorId>
  </sponsor>
  <funder id="Funder12811-0">
    <name>Chiang Mai University (Thailand) - Endowment Fund for Medical Research, Faculty of Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2004-11-02T00:00:00.000Z">22569553</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An adaptogenic role for omega-3 fatty acids in stress: a randomised placebo controlled double blind intervention study (pilot)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22569553</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f477319e-8699-4f68-9072-c0dcf97d6a37">
	  <name>P.O. Box 157</name>
	  <address/>
	  <city>Lismore</city>
	  <state/>
	  <country>Australia</country>
	  <zip>2480</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>University staff who scored ‚â•17 on the Perceived Stress Scale</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Perceived stress</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Stress</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 6 g fish oil per day, containing 1.5 g docosahexaenoic acid (DHA)
Control: 6 g a day of olive oil (placebo)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15566625 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f51e799f-3e6a-4899-a21b-fdf5735e91a3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15566625"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12787-0</funderId>
      <contactId>Contact50253_12787</contactId>
      <sponsorId>Sponsor48624</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50253_12787">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Myers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48624">
    <organisation>Australian Centre for Complementary Medicine, Education and Research (ACCMER)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12787-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-10-05T00:00:00.000Z">84128484</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Central Serous Retinopathy (CSR) is a retinal disorder affecting young adults, characterized clinically by a well-defined, translucent, circumscribed detachment of neurosensory retina at the posterior pole, usually involving the macula. The detachment results from accumulation of transparent fluid in the potential space between retinal pigment epithelial layer and the neurosensory retina.

Hypothesis:
To evaluate the efficacy of diode laser photocoagulation in patients with central serous retinopathy (CSR) and to compare it with the effects of argon green laser.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84128484</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d9e2f7d4-7e11-410b-a172-3d17526d3df0">
	  <name>E- 18, Hudco palace</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110049</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients of unilateral type 1 CSR</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Central Serous Retinopathy (CSR)</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Diseases of the retina</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Diode Laser photocoagulation
2. Argon green laser photocoagulation
3. Fluorescein Angiography</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15516262 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b187c672-8753-4d4c-b596-4f9465e12385" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-10-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15516262"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12764-0</funderId>
      <contactId>Contact50221_12764</contactId>
      <sponsorId>Sponsor48589</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50221_12764">
    <title>Dr</title>
    <forename>Lalit</forename>
    <surname>Verma</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>E- 18, Hudco palace
Andrews ganj</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110049</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lalitverma@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48589">
    <organisation>All-India Institute of Medical Sciences (AIIMS) (India) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lalitverma@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413618.9</gridId>
    <rorId>https://ror.org/02dwcqs71</rorId>
  </sponsor>
  <funder id="Funder12764-0">
    <name>All-India Institute of Medical Sciences (AIIMS) (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-09-10T00:00:00.000Z">32203485</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to determine the effect on response of including a lottery incentive in health surveys</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32203485</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7128135-dc10-458a-a498-bcf364608eea">
	  <name>Department of General Practice</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>General adult population receiving health survey</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>8645</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>8645</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Health survey incentives</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Lottery style incentive versus no incentive</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533256 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ef263ca9-2ea2-4d91-bb0f-c0916c5ef6cc" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533256"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11346-0</funderId>
      <contactId>Contact41809_11346</contactId>
      <sponsorId>Sponsor39556</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41809_11346">
    <title>Dr</title>
    <forename>Lesley</forename>
    <surname>Roberts</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice
University of Birmingham
Edgbaston</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 3356</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.roberts@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39556">
    <organisation>University of Birmingham (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Edgbaston</address>
      <city>Birmingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 3356</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.roberts@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6572.6</gridId>
    <rorId>https://ror.org/03angcq70</rorId>
  </sponsor>
  <funder id="Funder11346-0">
    <name>Internally funded by the Department of Primary Care and General Practice, University of Birmingham (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-08T00:00:00.000Z">41238928</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient care compared with hospitalisation in low-risk patients with community-acquired pneumonia: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41238928</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FIS 00/0438</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="313518bc-7c3a-4b8b-ae2a-f3b26c85b90c">
	  <name>Hospital Universitari de Bellvitge</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>224 immunocompetent adults in risk classes II or III (Pneumonia Severity Index ‚â§90 points), without extenuating conditions diagnosed with community-acquired pneumonia in the emergency department.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>224</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>224</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Community-Acquired Pneumonia</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomly assigned to outpatient care or hospitalisation, and received oral or switch therapy with levofloxacin, respectively.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15684204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ace0fe9d-d1da-4129-8d7f-231c0d3ca2d4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15684204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11340-0</funderId>
      <funderId>Funder11340-1</funderId>
      <funderId>Funder11340-2</funderId>
      <contactId>Contact41801_11340</contactId>
      <sponsorId>Sponsor39547</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41801_11340">
    <title>Dr</title>
    <forename>Jordi</forename>
    <surname>Carratala</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital Universitari de Bellvitge
Feixa Llarga s/n
L¬¥Hospitalet</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 932607625</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jcarratala@wanadoo.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39547">
    <organisation>National Health Service (Spain)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Sinesio Delgado 4</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417198.2</gridId>
    <rorId>https://ror.org/04t4b6y41</rorId>
  </sponsor>
  <funder id="Funder11340-0">
    <name>Fondo de Investigacion Sanitaria (FIS) (Spain) - ref: 00/0438</name>
    <fundRef/>
  </funder>
  <funder id="Funder11340-1">
    <name>Aventis (Spain)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11340-2">
    <name>University of Barcelona (Spain) - Fellowship grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-08-31T00:00:00.000Z">45683816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomised trial</title>
      <scientificTitle/>
      <acronym>Saffron Project</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45683816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>555</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="00cd315c-e93a-49f2-b8a7-60f220bfcaa6">
	  <name>Roozbeh Psychiatric Hospital</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>13337</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Thirty adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) for major depression based on the structured clinical interview for DSM IV participated in the trial
2. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In this double-blind, single-centre trial, patients were randomly assigned to receive capsule of saffron 30 mg/day (10 mg three times a day [TDS]) (Group 1) and capsule of imipramine 100 mg/day (33.3 mg TDS) (Group 2) for a 6-week study.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Crocus sativus L., imipramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15341662 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="df316b15-fbb5-4d6f-b588-0b98f3578e47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15341662"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11335-0</funderId>
      <contactId>Contact41794_11335</contactId>
      <sponsorId>Sponsor39540</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41794_11335">
    <title>Prof</title>
    <forename>Shahin</forename>
    <surname>Akhondzadeh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 5412222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sakhond@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39540">
    <organisation>Roozbeh Psychiatric Hospital (Iran)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>South Kargar</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 5412222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sakhond@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416042.5</gridId>
    <rorId>https://ror.org/019mzt973</rorId>
  </sponsor>
  <funder id="Funder11335-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-08-31T00:00:00.000Z">67363048</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhoea: a randomised, double-blind, placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67363048</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1992-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Peru</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6cf75c4b-5a07-4d6f-a3ee-242275b665b7">
	  <name>Av. El Polo 740 Of. C-410</name>
	  <address/>
	  <city>Lima</city>
	  <state/>
	  <country>Peru</country>
	  <zip>033</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Male infants aged 3 - 36 months brought for treatment of acute watery diarrhoea with mild-moderate dehydration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>179</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>179</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1992-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute watery diarrhoea</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diarrhoea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Oral rehydration
2. Feeding with age-appropiate infant's food
3. Randomised to receive a milk formula with or without Lactobacillus casei strain GG</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345099 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="86c488cd-ab70-4372-b632-29228fafb583" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345099"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11338-0</funderId>
      <contactId>Contact41799_11338</contactId>
      <sponsorId>Sponsor39545</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41799_11338">
    <title>Dr</title>
    <forename>Eduardo</forename>
    <surname>Salazar-Lindo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. El Polo 740 Of. C-410</address>
      <city>Lima</city>
      <country>Peru</country>
      <zip>033</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+51 1 435 7800</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">edsalaza@ec-red.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39545">
    <organisation>Universidad Peruana Cayetano Heredia (Peru)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Honorio Delgado 430</address>
      <city>Lima</city>
      <country>Peru</country>
      <zip>031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmaster@upch.edu.pe</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.11100.31</gridId>
    <rorId>https://ror.org/03yczjf25</rorId>
  </sponsor>
  <funder id="Funder11338-0">
    <name>The study was supported by a grant from Valio Ltd, Helsinki (Finland) to the Child Health Foundation, Columbia, Maryland (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-08-03T00:00:00.000Z">74278823</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Explaining computation of predictive values: 2 x 2 table versus frequency tree - a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74278823</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0327785d-2236-4e61-8d2a-1306cef04c57">
	  <name>Martin-Luther-King Platz 6</name>
	  <address/>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20146</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Students without prior statistical training</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>184</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>184</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Statistical analyses: patients in decision making on diagnostic procedures</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of two visual helps to support computations of predictive values: 2x2 table versus frequency tree</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15301689 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="703e7e75-52cd-4150-ae9d-03ad8775c53d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-10T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15301689"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11308-0</funderId>
      <contactId>Contact41759_11308</contactId>
      <sponsorId>Sponsor39504</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41759_11308">
    <title>Mrs</title>
    <forename>Anke</forename>
    <surname>Steckelberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martin-Luther-King Platz 6</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20146</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)40 42838 3528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ASteckelberg@uni-hamburg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39504">
    <organisation>Robert-Bosch Stiftung (Robert-Bosch Foundation) (Germany) </organisation>
    <website>http://www.bosch-stiftung.de/content/language1/html/12760.asp</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Heidehofstr. 31</address>
      <city>Stuttgart</city>
      <country>Germany</country>
      <zip>70005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ingrid.Wuenning@bosch-stiftung.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418579.6</gridId>
    <rorId>https://ror.org/012kqkf58</rorId>
  </sponsor>
  <funder id="Funder11308-0">
    <name>Robert-Bosch Stiftung (Robert-Bosch Foundation) (Germany)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001646</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-07-27T00:00:00.000Z">36478292</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of bright light and exercise for depressive symptoms</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36478292</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-11-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="26505dac-a093-4519-a20b-99cdad17d177">
	  <name>National Public Health Institute</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>FIN-00300</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>120 - 124 healthy, working-age volunteers recruited through occupational health centres</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>98</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>98</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-11-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depressive symptoms</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Aerobic exercise in bright light, aerobic exercise in normal gym lighting, stretching/relaxation in bright light</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15306031 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e418b103-dfba-47ae-b03d-bdf5c01336a7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-11T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15306031"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11302-0</funderId>
      <funderId>Funder11302-1</funderId>
      <contactId>Contact41753_11302</contactId>
      <sponsorId>Sponsor39498</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41753_11302">
    <title>Dr</title>
    <forename>Timo</forename>
    <surname>Partonen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Public Health Institute
Department of Mental Health and Alcohol Research
Mannerheimintie 166</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>FIN-00300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">timo.partonen@ktl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39498">
    <organisation>National Public Health Institute (Finland)</organisation>
    <website>http://www.ktl.fi/portal/english/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Department of Mental Health and Alcohol Research
Mannerheimintie 166</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>FIN-00300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jouko.lonnqvist@ktl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.14758.3f</gridId>
    <rorId>https://ror.org/03tf0c761</rorId>
  </sponsor>
  <funder id="Funder11302-0">
    <name>The Signe and Ane Gyllenberg Foundation (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11302-1">
    <name>The Finnish Foundation for Psychiatric Research (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-07-20T00:00:00.000Z">72263357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Misoprostol for treating postpartum haemorrhage: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72263357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CRHS010215a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f87ff49-d857-4203-8579-57dbf58192b5">
	  <name>P Bag X9047</name>
	  <address/>
	  <city>East London</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>5201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women with postpartum haemorrhage defined as vaginal bleeding after childbirth considered to be excessive, and considered likely to be due to inadequate uterine contraction</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postpartum haemorrhage</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Intervention group: Misoprostol 200 ¬µg tablets. Each woman receives 1 tablet orally, 2 tablets sublingually and 2 tablets rectally.
2. Control group: identical placebo tablets. Each woman receives 1 tablet orally, 2 tablets sublingually and 2 tablets rectally.
(All women receive routine accepted treatment for postpartum haemorrhage)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15298718 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4aa01149-6a07-4376-ae7f-99ba16586d7a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15298718"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11288-0</funderId>
      <contactId>Contact41739_11288</contactId>
      <sponsorId>Sponsor39484</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41739_11288">
    <title>Prof</title>
    <forename>G Justus</forename>
    <surname>Hofmeyr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P Bag X9047</address>
      <city>East London</city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)832809402</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gjh@global.co.za</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39484">
    <organisation>University of the Witwatersrand (South Africa)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>7, York Rd
Parktown</address>
      <city>Johannesburg</city>
      <country>South Africa</country>
      <zip>2193</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)11 717 2000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gjh@global.co.za</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.11951.3d</gridId>
    <rorId>https://ror.org/03rp50x72</rorId>
  </sponsor>
  <funder id="Funder11288-0">
    <name>University of the Witwatersrand (South Africa) - No external funding; this trial was funded from the existing research unit budget, using full-time research staff.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-07-12T00:00:00.000Z">88246634</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88246634</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="53cfa744-2de9-437b-8d56-40a0e3ef93fa">
	  <name>Albert Schweitzerplaats 25</name>
	  <address/>
	  <city>Dordrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3318AT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with primary biliary cirrhosis or primary sclerosing cholangitis and chronic significant fatigue.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>33</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>33</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary biliary cirrhosis and primary sclerosing cholangitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diseases of liver</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fluvoxamine treatment (150 mg/day) for a six-week period versus treatment with placebo. A double-blind placebo-controlled randomised trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluvoxamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15251034 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2d12b9dd-bc3a-4e3c-8c77-630caf943cea" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15251034"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11281-0</funderId>
      <contactId>Contact41732_11281</contactId>
      <sponsorId>Sponsor39477</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41732_11281">
    <title>Dr</title>
    <forename>Pieter</forename>
    <surname>ter Borg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Albert Schweitzerplaats 25</address>
      <city>Dordrecht</city>
      <country>Netherlands</country>
      <zip>3318AT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)786541111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pterborg@zonnet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39477">
    <organisation>Foundation for Liver Research (Stichting Lever Onderzoek) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Erasmus Medical Centre
Dr. Molewaterplein 40</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015GD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 9222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.vanbuuren@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.488303.4</gridId>
    <rorId>https://ror.org/04hzejq44</rorId>
  </sponsor>
  <funder id="Funder11281-0">
    <name>Gastrostart foundation (The Netherlands) (ref: EUR 4537)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-06-08T00:00:00.000Z">11871179</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomised clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the present study was to investigate the efficacy, adverse effect and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11871179</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>T√ºrkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6665e5a3-ae07-4a54-aa6a-a10401d75830">
	  <name>Izzet Baysal Faculty of Medicine</name>
	  <address/>
	  <city>Bolu</city>
	  <state/>
	  <country>T√ºrkiye</country>
	  <zip>14280</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients suspected to have brucella infection on the basis of clinical (fever, limb and back pains, sweating, fatigue, hepatomegaly, splenomegaly, arthritis, sacroileitis, spondylitis, orchitis and headache) and laboratory findings were hospitalised. The diagnosis was based on the presence of signs and symptoms compatible with brucellosis including a positive agglutination titre (greater than or equal to 1/160) and/or a positive culture. All sera obtained from the patients were examined by serial dilution (from 1:10 to 1:1280) using bacterial antigen.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>29</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>29</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Brucellosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Zoonotic bacterial diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study was carried out in the Social Security Duzce Hospital and Abant Izzet Baysal Universty Duzce Medical School in Turkey. After obtaining informed consent, a detailed medical history was taken from each patient and a complete physical examination was performed. 

Patients who met the criteria for entry were randomly assigned to receive in a 1:1 ratio doxycycline plus rifampicin or ofloxacin plus rifampicin:
1. The doxycycline plus rifampicin group had 14 patients who received doxycycline 100 mg twice daily and rifampicin 600 mg once daily for 45 days
2. The ofloxacin plus rifampicin group had 15 patients who received ofloxacin 400 mg once daily and rifampicin 600 mg once daily for 30 days

Patients were hospitalised for at least 10 days at the beginning of treatment in order to monitor clinical response and potential side effects. The patients were assessed and laboratory tests were also performed during the therapy period in the 2nd, 4th, and 6th week of therapy. At the end of therapy, laboratory tests were reassessed at months 1, 2 and 3, as well as whenever clinical symptoms reappeared.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ofloxacin, rifampicin, doxycycline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15214959 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2f2e5e11-7980-4249-b8b0-5a2609021312" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-06-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15214959"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11244-0</funderId>
      <contactId>Contact41685_11244</contactId>
      <sponsorId>Sponsor39430</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41685_11244">
    <title>Dr</title>
    <forename>Oguz</forename>
    <surname>Karabay</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Izzet Baysal Faculty of Medicine
Infectious Diseases and Clinical Microbiology</address>
      <city>Bolu</city>
      <country>T√ºrkiye</country>
      <zip>14280</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor39430">
    <organisation>Izzet Baysal Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Oguz Karabay
Infectious Diseases and Clinical Microbiolgy</address>
      <city>Bolu</city>
      <country>T√ºrkiye</country>
      <zip>14280</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+90 374 253 4656 / 4140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drkarabay@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411082.e</gridId>
    <rorId>https://ror.org/01x1kqx83</rorId>
  </sponsor>
  <funder id="Funder11244-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-05-21T00:00:00.000Z">32823119</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of prize draw incentive on the response rate to a postal survey of obstetricians and gynaecologists: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32823119</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6f6da5e8-695a-4d36-8a2e-1e15e39fcb42">
	  <name>Birmingham Women's Hospital</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Gynaecologists</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1410</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1410</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Epidemiology/Response rates</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Non-monetary incentive versus no incentive.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15222889 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2c2fd244-2583-4756-a32a-e4af84daab1a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-06-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15222889"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11229-0</funderId>
      <contactId>Contact41666_11229</contactId>
      <sponsorId>Sponsor39411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41666_11229">
    <title>Dr</title>
    <forename>Thomas Justin</forename>
    <surname>Clark</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Birmingham Women's Hospital</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 4721377</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">justin.clark@bwhct.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39411">
    <organisation>Birmingham Women's Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Edgbaston</address>
      <city>Birmingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>B15 2TG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 4721377</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">justin.clark@bwhct.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.423077.5</gridId>
    <rorId>https://ror.org/00xe5zs60</rorId>
  </sponsor>
  <funder id="Funder11229-0">
    <name>Royal College of Obstetrics and Gynaecology (UK) - Endometriosis Millennium Fund</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2004-04-21T00:00:00.000Z">14429643</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial to assess the impact of an anti-thrombotic decision aid in patients with non-valvular atrial fibrillation</title>
      <scientificTitle/>
      <acronym>DAAFI</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14429643</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>I-10</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="837d1e58-bef0-4e1d-9fbb-f473097714c7">
	  <name>2E3.24 Walter Mackenzie Centre</name>
	  <address/>
	  <city>Edmonton</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2R7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Family physicians and their adult patients with non-valvular atrial fibrillation.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1100</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-valvular atrial fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Other forms of heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A prospective, multi-centre, two-arm cluster randomised controlled trial to evaluate whether an evidence-based patient decision aid for patients with non-valvular atrial fibrillation can improve the appropriate use of antithrombotic therapy (as defined by the 2001 American College of Chest Physicians [ACCP] Recommendations) by patients and their family physicians compared to usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in https://pubmed.ncbi.nlm.nih.gov/15128463 Protocol
2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16129870 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bbcc8be3-8144-47c6-b809-4401fdada367" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-05-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15128463"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="01205c8a-bb3f-449e-aafc-c33d598029b4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-08-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16129870"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11214-0</funderId>
      <funderId>Funder11214-1</funderId>
      <contactId>Contact41645_11214</contactId>
      <sponsorId>Sponsor39389</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41645_11214">
    <title>Dr</title>
    <forename>Finlay</forename>
    <surname>McAlister</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2E3.24 Walter Mackenzie Centre
8440 112 Street</address>
      <city>Edmonton</city>
      <country>Canada</country>
      <zip>T6G 2R7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor39389">
    <organisation>Canadian Stroke Network (Canada)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>451 Smyth Road</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8M5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder11214-0">
    <name>Canadian Stroke Network (I-10) (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11214-1">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-04-19T00:00:00.000Z">46889446</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled clinical trial of General Packet Radio Service (GPRS) mobile telephone technology for monitoring type 1 diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46889446</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="abc2198b-7abc-490b-9390-96fc7fd9f21a">
	  <name>Institute of Health Sciences</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX3 7LF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 17 to 30 years
2. With type 1 diabetes
3. HbA1c (haemoglobin A1c) between 8% and 11%</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 1 diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control arm: Collecting blood glucose data with a mobile phone.
Intervention arm: Collecting data and receiving regular feedback and interpretation of results.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16249542 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7233f395-bccd-4195-88b4-edfd2e081ff0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16249542"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5748-0</funderId>
      <contactId>Contact7181_5748</contactId>
      <sponsorId>Sponsor5345</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7181_5748">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Neil</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Health Sciences
Roosevelt Drive
Headington</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX3 7LF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 266 777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.neil@wolfson.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5345">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institute of Health Sciences
Roosevelt Drive
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 7LF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 266 777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.neil@wolfson.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder5748-0">
    <name>The Vodafone Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-23T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">27087076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving the effectiveness of community dental screening</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is a new model of school dental screening more cost effective and with proven benefits compared to existing dental screening practice and a health promotion programme designed to encourage dental visiting?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Agreed clinical criteria for referral following school screening</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 23/07/2007:
1. St Helens and Knowsley, Local Research Ethics Committee, approved on 19th April 2001
2. North Cheshire Ethics Committee, approved on 2nd March 2000</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27087076</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RHC28211</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="85c81336-d9f4-4ce0-9a9f-8520685b8fce">
	  <name>Chester and Halton Community NHS Trust</name>
	  <address/>
	  <city>Chester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CH2 1UL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1000 children</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>None</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oral health / stomatognathic diseases</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Oral health / stomatognathic diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>New model of school dental screening vs existing dental screening and a health promotion programme designed to encourage dental visiting.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16703094 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799446 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16998133 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17194071 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17183393 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5244b959-e1ea-4bbd-b22b-2f92e572a976" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16703094"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="96c9affa-3a6b-4d50-80a7-4bd7a68a3e32" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799446"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="c2cb07c8-bac3-4aca-b223-3e04ef0f3454" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16998133"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="7cd0acd8-dbba-449d-93f3-ad3f5a12fcaa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17194071"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="6f4fba4b-a713-45fd-8862-eb64b48a315b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17183393"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5964-0</funderId>
      <contactId>Contact7506_5964</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7506_5964">
    <title>Mr</title>
    <forename>Keith</forename>
    <surname>Milsom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chester and Halton Community NHS Trust
Department of Community Dentistry
Moston Lodge
Countess of Chester Health Park
Liverpool Road</address>
      <city>Chester</city>
      <country>United Kingdom</country>
      <zip>CH2 1UL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1244 364876</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Keith.Milsom@cahc-tr.nwest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5964-0">
    <name>NHS Executive North West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-25T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">71946848</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of a brief physiotherapy intervention in the community setting for patients with neck related pain compared with traditional physiotherapy management</title>
      <scientificTitle/>
      <acronym>SPRINTER</acronym>
      <studyHypothesis>1. Is a brief physiotherapy intervention (1-3 sessions) in patients with neck-related pain as effective as a traditional course of physiotherapy? 
2. What are the relative costs of using the brief intervention approach compared with traditional physiotherapy?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Neck Pain Questionnaire: a condition specific questionnaire measuring functional disability which has been developed from the Oswestry Disability Score for back pain patients 
2. SF-36: This is a generic health-related quality of life questionnaire including both psychological and physical factors 
3. EuroQol: This a generic quality of life measure required for the economic evaluation</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.hull.ac.uk/instrehab/research/sprinter.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 25/07/2007: 
1. Hull and East Riding Research Ethics Committee
2. Scarborough and North East Yorkshire Locally Organised Research Ethics Committee
3. South Humber Health Authority Local Research Ethics Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN71946848</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>rctc119 Klaber Moffett</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-10-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="43c0fe61-cef0-4b6d-bd55-9623154b9703">
	  <name>University of Hull</name>
	  <address/>
	  <city>Hull</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HU3 2PG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria updated as of 25/07/2007: 
1. A minimum age of 18 years
2. Neck pain of musculoskeletal origin lasting at least two weeks
3. Referred to a participating physiotherapy department and having consented to participate in the study
4. Willingness to be randomized; that is, no overwhelming preference for either intervention

Inclusion criteria provided at time of registration: 
Patients who are referred by their GPs to the participating community based physiotherapy departments for the management of neck related pain thought to be of musculoskeletal origin and corresponding to the diagnostic categories 1 and 2 (neck pain with or without referral to the proximal extremity) of the classification system proposed by the Quebec Task Force on Spinal Disorders.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>268</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>268</totalTarget>
      <exclusion>Exclusion criteria added as of 25/07/2007: 
1. Potentially serious pathology
2. Main pain below the elbow or in some other part of the body or coexisting &#147;serious other problem&#148; (such as capsulitis of the shoulder or tennis elbow) that would require additional treatment other than that required for the neck pain
3. Recent treatment for a neck problem (in the previous six weeks) or intention to pursue additional (private) treatment concurrent with that provided by the physiotherapy department
4.  Surgery on the neck</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-10-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Musculoskeletal diseases: Spinal conditions</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Spinal conditions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Brief intervention: problem solving approach encouraging self-help. It will consist of advice, including a home exercise programme, and incorporate cognitive behavioural principles.
2. Standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15585539 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fe0ddaa4-f5a5-4a66-9c69-c3fa096562f0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-01-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15585539"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6104-0</funderId>
      <contactId>Contact7385_6104</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7385_6104">
    <title>Dr</title>
    <forename>Jennifer</forename>
    <surname>Klaber Moffett</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Hull
Institute of Rehabilitation
215 Anlaby Road</address>
      <city>Hull</city>
      <country>United Kingdom</country>
      <zip>HU3 2PG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1482 675 610</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.moffett@hull.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6104-0">
    <name>NHS Executive Trent (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">23629430</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The role of bioglue in eliminating prolonged alveolar air leak in thoracic surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Will bioglue reduce required length of chest drainage and hospital stay by reducing persistent alveolar air leaks following major lung resection?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Duration of air leak
2. Duration of intercostal drainage
3. Duration of hospital stay
4. Incidence of complications</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23629430</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0201118681</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6a404ab3-e965-41d6-84b3-c431469c968a">
	  <name>Surgery</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW3 6NP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>104</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>104 patients</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Thoracic</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Thoracic</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Surgical treatment only vs surgical treatment and BioGlue</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16798309 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="536b9586-a531-4bae-8ec4-96839cdefed4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16798309"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5470-0</funderId>
      <contactId>Contact7008_5470</contactId>
      <sponsorId>Sponsor5287</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7008_5470">
    <title>Prof</title>
    <forename>P</forename>
    <surname>Goldstraw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Surgery
Royal Brompton &amp; Harefield NHS Trust
Sydney Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW3 6NP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7352 8121</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">P.Goldstraw@rbh.nthames.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5287">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5470-0">
    <name>Royal Brompton and Harefield NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2003-01-03T00:00:00.000Z">24540377</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The long term effectiveness of steroid injection for shoulder pain; a pragmatic randomised comparison with physiotherapy in primary care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the long term effectiveness of local steroid injections administered by general practitioners with practice based physiotherapy for treating patients presenting in primary care with new episodes of unilateral shoulder pain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was disability at 6 months measured using a shoulder disability Questionnaire.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes included: participants&#146; global assessment of change compared with baseline; rating of pain severity; impairment of function; severity of main complaint; ranges of movement; co-interventions.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24540377</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H0563</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="05ecefa1-57cd-4240-a6f8-e4189fc290f0">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Stoke-on-Trent</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST6 7AG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males and females over 18 years with a clinical diagnosis of unilateral shoulder pain
2. First consultation with GP for this episode
3. Ability to understand and give informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>207</totalTarget>
      <exclusion>A history of inflammatory arthritis, polymyalgia rheumatica, or gross structural or neurological abnormality of the shoulder; contraindications to local steroid injection; history or examination leading to a suspicion of potentially serious disease; referred pain from neck or internal organs; clinical findings of ruptured rotator cuff; previous fracture or surgery to shoulder, upper limb, neck, or thorax; previous physical therapy for shoulder pain within the past 12 months; pregnancy or breast feeding.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Shoulder pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Shoulder pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Methyl prednisolone (40 mg) and lignocaine by local injection
2. Physiotherapy</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methyl prednisolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12695148 Results
2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14965386 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="35a4f4cf-4785-41d4-8d9c-c9e216a417a6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12695148"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="e52a019d-d63a-4abc-8218-f3ffe9a0350c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14965386"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1508-0</funderId>
      <contactId>Contact5073_1508</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5073_1508">
    <title>Dr</title>
    <forename>EM</forename>
    <surname>Hay</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Haywood Hospital
High Lane
Burslem</address>
      <city>Stoke-on-Trent</city>
      <country>United Kingdom</country>
      <zip>ST6 7AG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 715444</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.m.hay@cphc.keele.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1508-0">
    <name>Arthritis Research Campaign</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2003-01-03T00:00:00.000Z">34466933</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised placebo-controlled trial of local steroid injection and nonsteroidal anti-inflammatory tablets for the treatment of tennis elbow</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the clinical effectiveness of local corticosteroid injections, standard non-steroidal anti-inflammatory drugs and simple analgesics for the treatment of lateral epicondylitis in primary care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Participants' global assessment of improvement (5-point scale) at 4 weeks.</primaryOutcome>
      <secondaryOutcome>1. Pain severity
2. Impairment of function
3. Severity of main complaint
4. Disability
5. Grip strength
6. Local tenderness
7. Co-interventions
8. Time off paid employment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34466933</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H0526</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1539b8c7-cbf1-4cf8-b49e-431827ff20ba">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Stoke-on-Trent</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST6 7AG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consecutive patients aged 18-70 years who consulted their GP with a new episode of lateral epicondylitis (pain and tenderness in the lateral region of the elbow and no consultation with symptoms in the same elbow in the preceding 12 months) during November 1995 to December 1997.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>164</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>164</totalTarget>
      <exclusion>1. History of inflammatory arthritis or gross structural abnormality of the elbow
2. Contraindications to non-steroidal anti-inflammatories or local steroid injection
3. Pregnancy or breast feeding</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tennis elbow</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Lateral epicondylitis (tennis elbow)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Methyl prednisolone (20 mg) and lignocaine by local injection
2. Naproxen 500 mg bd for 2 weeks versus placebo tablets</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>local corticosteroid injections, standard non-steroidal anti-inflammatory drugs and simple analgesics</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10514160 Results
2002 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11932058
2002 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12019587</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="131a783c-5aee-4f99-a6b1-8546d2696c86" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-10-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10514160"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="998c7d20-c2b4-4d97-b4cc-d33211da49cf" outputType="abstract" artefactType="ExternalLink" dateCreated="2002-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11932058"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="d7db9f23-1aa1-4c0c-8521-fd505e54d875" outputType="abstract" artefactType="ExternalLink" dateCreated="2002-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12019587"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1488-0</funderId>
      <contactId>Contact5073_1488</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5073_1488">
    <title>Dr</title>
    <forename>EM</forename>
    <surname>Hay</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Haywood Hospital
High Lane
Burslem</address>
      <city>Stoke-on-Trent</city>
      <country>United Kingdom</country>
      <zip>ST6 7AG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 715444</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.m.hay@cphc.keele.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1488-0">
    <name>Arthritis Research Campaign</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-08-02T00:00:00.000Z">45577048</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised double-blind placebo controlled trial of effect of Ginkgo biloba on cognitive function in mild-moderate dementia</title>
      <scientificTitle/>
      <acronym>DIGGER</acronym>
      <studyHypothesis>Null Hypothesis: high purity ginkgo biloba extract does not improve cognition quality of life or carer burden in individuals with mild-moderate dementia. NB: this study will also assess the magnitude of the Hawthorne effect in dementia trials.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) at six months.</primaryOutcome>
      <secondaryOutcome>All at six months:
1. Participant: Quality of Life scale in Alzheimer&#146;s disease (QoL-AD), Neuropsychiatric Inventory questionnaire (NPI), Geriatric Evaluation by Relative's Rating Instrument (GERRI), adverse events
2. Carer: European Quality of life questionnaire (EQ-5D), Zarit caregiver Burden Interview (ZBI)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from Multi-centre Research Ethics Committee (ref: MREC/02/6/35).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45577048</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>QRD/2001/01/07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled parallel group study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cc405a25-41f9-4ecf-9d89-481af716fea6">
	  <name>Senior Lecturer</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W10 6DZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 55 years and over
2. Clinician's diagnosis of dementia
3. Presence of a carer 
4. Consent of patient and carer
5. Sufficient command of English to complete questionnaires
6. Mini Mental State Examination (MMSE-23) score of 15 - 24</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Target: 200</totalTarget>
      <exclusion>1. Commencement of acetylcholinesterase therapy within two months of recruitment
2. Current anticoagulant therapy
3. Abnormal clotting profile</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dementia</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Dementia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. The active intervention will be concentrated, standardised Ginkgo biloba extract (25% active Ginkgo-flavoneglycosides), prepared according to accepted guidelines in a 60 mg tablet (EGB-761, Schwabe)
2. The placebo will be 60 mg of inert lactose with 2 mg quinine sulphate</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ginkgo extract</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17608932 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="85921285-2a7b-4032-a9b4-e0a5fae3150b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17608932"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1428-0</funderId>
      <contactId>Contact5090_1428</contactId>
      <sponsorId>Sponsor53226</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5090_1428">
    <title>Dr</title>
    <forename>James</forename>
    <surname>Warner</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Senior Lecturer
Imperial College School of Medicine
St Charles Hospital
Exmoor Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W10 6DZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 8962 4101</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.warner@ic.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53226">
    <organisation>Alzheimer's Society (UK)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Gordon House
10 Greencoat Place</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1P 1PH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7306 0606</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">enquiries@alzheimers.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.432249.a</gridId>
    <rorId>https://ror.org/0472gwq90</rorId>
  </sponsor>
  <funder id="Funder1428-0">
    <name>Alzheimer's Society (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000320</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-03-28T00:00:00.000Z">85520592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Spironolactone AmiLoride Thiazide study of aldosterone sensitive hypertension</title>
      <scientificTitle/>
      <acronym>SALT</acronym>
      <studyHypothesis>Spironolactone will reduce systolic Blood Pressure (sBP) by more than 5 mmHg than bendrofluazide.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>sBP and plasma renin on spironolactone versus bendroflumethiazide.</primaryOutcome>
      <secondaryOutcome>1. sBP on amiloride versus other diuretics.
2. Further measures of natriuresis.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval information not required at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85520592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PG/02/014/13511</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d489e3d4-d4dc-40ce-9c97-43db66105fee">
	  <name>Clinical Pharmacology Unit</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB2 2QQ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Hypertension (requiring treatment according to British Hypertension Society [BHS] criteria)
2. Aldosterone/renin ratio &gt;400
3. Either Systolic Blood Pressure (SBP) on spironolactone more than or equal to 20 mmHg, during previous open-label treatment or Plasma renin activity less than 0.2 pmol/ml/h and response to spironolactone not previously tested</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Contraindications to study drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Low-renin hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Spironolactone (50 &amp; 100 mg), amiloride (20 &amp; 40 mg), bendrofluazide (2.5 &amp; 5 mg), irbesartan (150 mg), placebo.

The lower dose of each will be re-encapsulated in identical capsules. Patients will take two capsules each day, consisting of either two placebos, or one each active and placebo (ie low-dose active), or two active (ie high-dose active).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Spironolactone, amiloride, bendrofluazide and  irbesartan.</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17606839 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="95dafafc-49cd-4b80-87ea-47b4e38a578b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17606839"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1384-0</funderId>
      <contactId>Contact5364_1384</contactId>
      <sponsorId>Sponsor5027</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5364_1384">
    <title>Prof</title>
    <forename>Morris J</forename>
    <surname>Brown</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Pharmacology Unit
Level 6  ACCI
Box 110
Addenbrooke's Hospital</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB2 2QQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1223 336743</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mjb14@medschl.cam.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5027">
    <organisation>British Heart Foundation (UK)</organisation>
    <website>http://www.bhf.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>14 Fitzhardinge Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1H 6DH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7935 0185</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@bhf.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452924.c</gridId>
    <rorId>https://ror.org/02wdwnk04</rorId>
  </sponsor>
  <funder id="Funder1384-0">
    <name>British Heart Foundation (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000274</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2000-10-25T00:00:00.000Z">14969683</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of open versus laparoscopic colposuspension for genuine stress incontinence</title>
      <scientificTitle/>
      <acronym>MRC COLPO Trial</acronym>
      <studyHypothesis>To compare the cure rates in the two intervention groups.  Additionally the two procedures will be compared in terms of perioperative morbidity, recovery time, incidence of postoperative voiding dysfunction, de novo detrusor instability and health economic costs to NHS and patient.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary Outcomes: complete cure of stress incontinence at 24 and 48 months. Symptom improvement classified as: Complete (have never leaked since surgery and no leakage objectively demonstrated), 
Acceptable Improvement (matched patient expectations), Inadequate Improvement, No improvement, Worse. Levels of significant operative morbidity.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14969683</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G9721060</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="643f189a-e98c-4f72-8ac9-b725a83260d8">
	  <name>Academic Unit of Obstetrics &amp; Gynaecology Reproductive Healthcare</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M13 0JH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Any woman for whom a decision has been made to perform a colposuspension for cystometrically proven genuine stress incontinence. 
2. Women who have had an anterior colporrhaphy would be eligible as it is considered that their inclusion is pragmatic reflecting everyday practice.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>290</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>290</totalTarget>
      <exclusion>1. Women in whom bladder neck surgery is contraindicated; 
2. Women with detrusor instability.
3. Women who have had previous retropubic bladder neck surgery (colposuspension or sling procedure) or sacrocolpopexy.  
4. Women who are unhappy to be randomised to laparoscopic colposuspension.  
5. Women considered too obese for open colposuspension.  (Laparoscopic colposuspension is only to be available as part of the trial.)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stress incontinence</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Stress incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The interventions under study will be open or laparoscopic colposuspension.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16956332 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="15a526c0-a2df-411a-96d0-e3c7de6b4c93" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16956332"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1012-0</funderId>
      <contactId>Contact5320_1012</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5320_1012">
    <title>Prof</title>
    <forename>Henry C</forename>
    <surname>Kitchener</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Unit of Obstetrics &amp; Gynaecology Reproductive Healthcare
University of Manchester
St Mary's Hospital
Whitworth Park</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M13 0JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 276 6646</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">henry.kitchener@cmmc.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1012-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial></allTrials>